Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDV Database Cohort Study on Venous Thromboembolism Risk with Bevacizumab Biosimilar CTNK vs Comparator
jRCT2031250738Active, not recruiting
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of bevacizumab in colorectal cancer (CRC), breast cancer, ovarian cancer and 1 more (2 arms), sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Incidence of venous thromboembolism (VTE). Started Nov 2022; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)breast cancerovarian cancermalignant glioma
Beyond the preview
Go deeper on jRCT2031250738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250738.